Skye Bioscience, Inc.
SKYE
$1.11
-$0.10-8.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.21% | -13.85% | 18.58% | 49.22% | -14.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 128.41% | 106.18% | 116.03% | 123.32% | 26.16% |
| Operating Income | -128.41% | -106.18% | -116.03% | -123.32% | -26.16% |
| Income Before Tax | -141.28% | -0.21% | 12.94% | 29.45% | 50.75% |
| Income Tax Expenses | -46.53% | -46.53% | 80.36% | 180.56% | 94.23% |
| Earnings from Continuing Operations | -141.19% | -0.20% | 12.92% | 29.43% | 50.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.19% | -0.20% | 12.92% | 29.43% | 50.74% |
| EBIT | -128.41% | -106.18% | -116.03% | -123.32% | -26.16% |
| EBITDA | -126.82% | -104.51% | -114.86% | -123.16% | -26.21% |
| EPS Basic | -53.47% | 72.64% | 81.59% | 87.22% | 90.35% |
| Normalized Basic EPS | -43.61% | 16.09% | 55.22% | 68.65% | 83.00% |
| EPS Diluted | -53.34% | 72.67% | 81.61% | 87.21% | 90.35% |
| Normalized Diluted EPS | -43.61% | 16.09% | 55.22% | 68.65% | 83.00% |
| Average Basic Shares Outstanding | 34.82% | 81.82% | 201.16% | 420.68% | 538.35% |
| Average Diluted Shares Outstanding | 34.82% | 81.82% | 201.16% | 420.68% | 538.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |